The U.S. Food and Drug Administration clarified that the death of the six candidates was not related to the Pfizer-BioNTech vaccine trials.
On December 10, FDA released a briefing document clarifying the death of 6 participants in which 2 participants were included in the BNT162b2 group and 4 participants in the placebo group. (Ref Page - 50/92)
One of the vaccine recipients had a cardiac arrest 62 days after a second dose of the two-dose vaccination and died three days later. The other died from arteriosclerosis three days after a first dose of the vaccination. One of the placebo recipients died from myocardial infarction, another from hemorrhagic stroke, and two others from unknown causes, and none of those deaths were linked to the vaccine. (ref page no 50).
Further, Margaret Keenan, the first person to receive the COVID-19 vaccine, was well enough to be discharged from the hospital on December 09, and she was far from being in a critical condition.
On December 08, 2020, the U.K. began its vaccination program with priority recipients, including healthcare staff. Two NHS staff members who had the jab suffered allergic reactions. After which, Dr. June Raine, Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), on December 09, 2020, issued updated guidelines to the COVID-19 vaccination centers about the vaccine's possible allergic reactions. The guidance suggested that people with a history of significant allergic reactions should not have the Pfizer/BioNTech COVID vaccine.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.